Clinical Trial Update: Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study evaluated the behavior of dabigatran etexilate during haemodialysis to assess drug clearance in patients with cardiovascular dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Chronic Kidney Disease

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Cardiovascular Diseases, Kidney Failure, Chronic | Phase 1 | Status: COMPLETED | Results posted: 2012-07-27